James R Shoblock
Overview
Explore the profile of James R Shoblock including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
444
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Characterization of a Selective, Orally Available, and Brain Penetrant Small Molecule GPR139 Agonist
Shoblock J, Welty N, Fraser I, Wyatt R, Lord B, Lovenberg T, et al.
Front Pharmacol
. 2019 Apr;
10:273.
PMID: 30949055
Recently, our group along with another demonstrated that GPR139 can be activated by L-phenylalanine (L-Phe) and L-tryptophan (L-Trp) at physiologically relevant concentrations. GPR139 is discretely expressed in brain, with highest...
2.
Lord B, Aluisio L, Shoblock J, Neff R, Varlinskaya E, Ceusters M, et al.
J Pharmacol Exp Ther
. 2014 Oct;
351(3):628-41.
PMID: 25271258
In the central nervous system, the ATP-gated Purinergic receptor P2X ligand-gated ion channel 7 (P2X7) is expressed in glial cells and modulates neurophysiology via release of gliotransmitters, including the proinflammatory...
3.
Winterdahl M, Audrain H, Landau A, Smith D, Bonaventure P, Shoblock J, et al.
J Nucl Med
. 2014 Mar;
55(4):635-9.
PMID: 24614224
Unlabelled: Neuropeptide Y2 (NPY2) receptors are implicated in diverse brain disorders, but no suitable PET radiotracers are currently available for studying NPY2 receptors in the living brain. We developed a...
4.
Bhattacharya A, Wang Q, Ao H, Shoblock J, Lord B, Aluisio L, et al.
Br J Pharmacol
. 2013 Jul;
170(3):624-40.
PMID: 23889535
Background And Purpose: An increasing body of evidence suggests that the purinergic receptor P2X, ligand-gated ion channel, 7 (P2X7) in the CNS may play a key role in neuropsychiatry, neurodegeneration...
5.
Shoblock J, Welty N, Aluisio L, Fraser I, Motley S, Morton K, et al.
Psychopharmacology (Berl)
. 2010 Dec;
215(1):191-203.
PMID: 21181123
Rationale: Orexin-1 receptor antagonists have been shown to block the reinforcing effects of drugs of abuse and food. However, whether blockade of orexin-2 receptor has similar effects has not been...
6.
Galici R, Rezvani A, Aluisio L, Lord B, Levin E, Fraser I, et al.
Psychopharmacology (Berl)
. 2010 Nov;
214(4):829-41.
PMID: 21086115
Rationale: A few recent studies suggest that brain histamine levels and signaling via H(3) receptors play an important role in modulation of alcohol stimulation and reward in rodents. Objective: The...
7.
Shoblock J, Welty N, Nepomuceno D, Lord B, Aluisio L, Fraser I, et al.
Psychopharmacology (Berl)
. 2009 Dec;
208(2):265-77.
PMID: 19953226
Rationale: The lack of potent, selective, brain penetrant Y(2) receptor antagonists has hampered in vivo functional studies of this receptor. Objective: Here, we report the in vitro and in vivo...
8.
Welty N, Shoblock J
Psychopharmacology (Berl)
. 2009 Oct;
207(3):433-8.
PMID: 19795107
Rationale: Histamine H3 receptors (H3R) are presynaptic heteroreceptors that negatively modulate the release of histamine and other neurotransmitters such as acetylcholine. Blocking H3 receptors with antagonists/inverse agonists has been shown...
9.
Shoblock J
CNS Drug Rev
. 2007 Apr;
13(1):107-36.
PMID: 17461893
The NOP receptor (formerly referred to as opiate receptor-like 1, ORL-1, LC132, OP(4), or NOP(1)) is a G protein-coupled receptor that shares high homology to the classic opioid MOP, DOP,...
10.
Shoblock J, Maidment N
Neuropsychopharmacology
. 2005 Jun;
31(1):171-7.
PMID: 15956992
Naloxone administration produces a robust conditioned place aversion (CPA) in opiate-naive rodents by blocking the action of enkephalins at mu opioid receptors. This aversive response is potentiated by prior exposure...